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Fig. 1. Rates (cases per 100,000 population) of invasive pneumococcal disease in
US children <5 years of age before and after introduction of 7-valent pneumococcal
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ublic health impact of pneumococcal vaccination
This discussion is based on a presentation given at a satellite
ymposium held in Buenos Aires, Argentina, on November 20,
009, at the 6th World Congress of the World Society for Pediatric
nfectious Diseases.
The introduction of the 7-valent pneumococcal conjugate
accine (PCV7) has not only dramatically reduced the incidence
f invasive pneumococcal disease (IPD), pneumonia, and otitis
edia (OM) worldwide among vaccinated infants and children,
ut it has also led to reductions in nasopharyngeal carriage of
accine serotypes, antibiotic use and resistance, ofﬁce visits,
nd the incidence of pneumonia among nonvaccinated children
nd adults through indirect herd immunity effects. PCV7 led to
ramatic declines in IPD caused by vaccine serotypes in children
5 years of age (Figure 1), as demonstrated in a study from the
ctive Bacterial Core Surveillance (ABCS) Program of the Emerging
nfections Program Network of the Centers for Disease Control and
revention (CDC).1 This study compared the rates of IPD among
hildren <5 years of age (n=1,312,144) by serotype during a 6-year
eriod, beginning 2 years prior to the introduction of PCV7 in 2000
nd continuing for 4 years afterward. The overall annual rate of
PD among children <5 years of age decreased from an average of
5.2 cases per 100,000 population during 1998–1999 to 22.6 cases
er 100,000 in 2004. There was a marked decrease in the rate of
isease due to vaccine serotypes, from an annual average of 78.9
ases per 100,000 population during 1998–1999 to 2.7 cases per
00,000 in 2004. The data suggest that disease due to nonvaccine
erotypes mitigated the decline in IPD incidence, underscoring the
eed for increased pneumococcal serotype coverage.
The ABCS2 found that IPD caused by penicillin-resistant strains
ecreased by 81% (95% CI, 80–82), from a peak of 70.3 per 100,000
opulation in 1999 to 13.1 per 100,000 in 2004. A decrease in cases
f penicillin-susceptible IPD also occurred. The decrease in the
ate of antibiotic-nonsusceptible IPD in young children after the
ntroduction of PCV7 suggests that pneumococcal vaccination may
ave the practical beneﬁt of reducing the number of treatment
ailures in children. The study also documented reductions in
ates of IPD caused by nonsusceptible strains in older children and
dults who were not vaccinated. Rates of penicillin-nonsusceptible
PD decreased by 60% among children 2–4 years of age, 41% among
ersons 5–19 years of age, 51% among persons 20–39 years of age,
nd 36% in persons 40–64 years of age (Figure 2). Among adults
65 years of age, the age groupwith the highest rates of prevaccine
ig. 2. Indirect effect of 7-valent pneumococcal conjugate vaccine (PCV7) on invasive pneu
opulation) in persons ≥2 years of age in the United States from 1996 to 2004. Based o
IC, 4g/mL; resistant MIC, ≥8g/mL). Adapted with permission from Kyaw et al.2 Copconjugate vaccine (PCV7). Latest published data from the US Centers for Disease
Control and Prevention Active Bacterial Core Surveillance program. Adapted with
permission from Hicks et al.1 © 2007 by the Infectious Diseases Society of America.
Published by The University of Chicago Press. All rights reserved.
penicillin-nonsusceptible IPD, the rates declined by 49%, from a
peak of 16.4 cases per 100,000 population in 1999 to 8.4 cases per
100,000 in 2004.
PCV7 also appears to have an indirect effect on the incidence of
IPD in infants 0–90days of age (i.e., prior to vaccination). A prospec-
tive, population-based surveillance study3 of infants (n =170) 0–90
days of age in 8 US states was conducted to determine the rates of
IPD by 30-day age groupings before and after PCV7 became avail-
able in 2000. Rates of vaccine-serotype isolates decreased by 67%,
from 7.3 (95% CI, 5.3–10.1) to 2.4 (95% CI, 1.6–3.8; P < 0.001) per
100,000 live births; rates of nonvaccine serotypes remained stable
(P=0.55). Mean rates of IPD for infants 0–90 days of age decreased
by 40%, from 11.8 (95% CI, 9.6–14.5) to 7.2 (95% CI, 5.6–9.4;
P=0.004) per 100,000 live births following vaccine introduction.Nasopharyngeal colonization is generally a prerequisite for
invasive and mucosal pneumococcal disease. The herd immunity
conferred by PCV7 may be due to a reduction in nasopharyngeal
carriage of vaccine serotypes in children receiving the vaccine.
In a study by O’Brien et al.4 children <2 years of age vaccinated
mococcal disease due to penicillin-nonsusceptible pneumococci (cases per 100,000
n 2004 Clinical and Laboratory Standards Institute MIC breakpoints (intermediate
yright © 2006 Massachusetts Medical Society. All right reserved.
Highlights of the 6th World Congress of the WSPID / Internat
Table 1
Estimated reduction in US admission rates for all-cause and pneumococcal pneu-
monia, 2004.*6
Age (y) All-Cause Pneumonia, % (CI) Pneumococcal Pneumonia, % (CI)
<2 39† (22–52) 65† (47–77)
18–39 26‡ (4–43) 30§ (9–47)
*Study design: Interrupted time-series analysis comparing estimated admission
rates for 2001–2004 (years following introduction of the 7-valent pneumococcal
conjugate vaccine [PCV7]) to expected rates calculated for 1997–1999 (pre-PCV7
years).
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P=0.008.
ith PCV7 were less likely to have nasopharyngeal colonization of
accine-type pneumococci than children vaccinated with control
accines. In addition, PCV7 demonstrated an indirect effect on
asopharyngeal carriage of vaccine serotypes in nonvaccinated
hildren (≤6 years of age) living in the community with vaccinated
hildren. Owing to this effect on nasopharyngeal carriage, the
ffectiveness of PCV7 has surpassed that predicted by efﬁcacy
rials.
A CDC surveillance study5 estimated that the number of cases of
PD caused by vaccine serotypes of Streptococcus pneumoniae that
ere averted in the United States in 2003 by direct and indirect
ffects of PCV7 were 9140 and 20,459, respectively (a 2.2-fold
ifference). An increased incidence of IPD due to nonvaccine
erotypes in children <5 years of age and in adults ≥40 years of age
as also reported (4789 cases in these age groups); however, the
agnitude of this replacement disease was small compared with
he overall reduction in cases (24,878) caused by vaccine serotypes.
An interrupted time-series analysis6 determined that hos-
ital admissions for pneumococcal pneumonia in children <2
ears of age declined by 65% over 4 years (2001–2004) after
he introduction of PCV7, while admissions for all-cause pneu-
onia declined by 39% during this period. Indirect effects of
CV7 in nonvaccinated adults were also observed, with signif-
cant reductions in hospital admission rates for pneumococcal
nd all-cause pneumonia among nonvaccinated adults 18–39
ears of age (Table 1). In a retrospective population study,7
ospitalization rates for pneumococcal pneumonia declined by
7.6%, while hospitalizations for all-cause pneumonia declined
y 52.4%.Multiple studies support the efﬁcacy of pneumococcal conju-
ate vaccination in the prevention of OM, recurrent OM, and the
eed for pressure equalization tube (PET) insertion. The efﬁcacy
f PCV7 against acute OM (AOM) was evaluated in original8 and
ig. 3. Estimated cost-effectiveness (cost per life-year gained in thousands) of 7-valent pn
=British pound; D =euro; P =payer perspective; S = societal perspective.13−18ional Journal of Infectious Diseases 14S (2010) e3–e10 e5
follow-up9 randomized, double-blind studies conducted by a
Finnish research group at the National Public Health Institute, and
by US investigators at the Northern California Kaiser Permanente
(NCKP) Vaccine Study Center.10,11 In the original Finnish study,8
children immunized with PCV7 had 6% fewer episodes of any-
cause AOM versus those receiving a hepatitis type B vaccine as
a control, 34% fewer culture-conﬁrmed pneumococcal episodes,
and 57% fewer episodes due to the serotypes contained in the
vaccine. In the follow-up study,9 vaccine efﬁcacy for PET insertion
was 39%.
In the NCKP study,10 children immunized with PCV7 had 7%
fewer OM episodes versus those receiving a meningococcus type
C conjugate vaccine, as well as 8.9% fewer OM visits. Recurrent OM
was reduced by 9.3–26% in vaccinated children versus controls,
and PET insertion was reduced by 20.1–24%.10,11
In a retrospective database analysis of a deﬁned population
that included an average of >500,000 person-years of observation
in children <2 years of age, Zhou et al.12 compared the number
of AOM-related visits, antibiotic prescriptions attributable to
AOM, and direct AOM costs in the prevaccine period (1997–1999)
with a postvaccine period (2004). The number of AOM-related
visits declined by 42.7%, the number of antibiotic prescriptions
attributable to AOM declined by 41.9%, and estimated direct AOM
costs declined by 32.3%. Although other factors, such as a concomi-
tant shift toward a “watch and wait” approach to the treatment
of AOM and the emergence of clinical practice guidelines that
recommended a reduction in the inappropriate use of antibiotics,
may have contributed to this trend, the ﬁndings of these studies
suggest that at least some of this decline may be attributable to
the introduction of PCV7 in 2000.
The impact of pneumococcal conjugate vaccination on the
incidence of pneumococcal disease in both vaccinated and nonvac-
cinated children and adults and the associated reductions in health
care utilization (e.g., reductions in hospital admissions, antibiotic
use, ofﬁce visits) make it a cost-effective medical intervention.
The impact of herd immunity on the cost-effectiveness of PCV7
has been evaluated in 6 published studies.13–18 All of these studies
indicate a dramatic reduction in medical costs due to the herd
immunity effect (Figure 3).
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able 1
revalence of nonvaccine serotypes after introduction of PCV7.
Reference Country/Region Description of Sample
Fenoll6 Greece Invasive isolates from children ≤
Brito7 Portugal Children <15 years of age with p
for SP in normal sterile body ﬂu
Cohen8 France Nasopharyngeal swabs from chi
months of age with AOM
Levy9 France Children 0–18 years of age with
meningitis
Ellis10 Buenos Aires, Argentina Patients admitted to a clinic wit
pneumococcal infection
Echániz-Aviles11 Mexico Invasive pediatric pneumococca
Delﬁno12 Uruguay Patients presenting with empye
2005–2009 (PCV7 introduced in
Mun˜oz-Almagro13 Barcelona, Spain Children with culture-proven IP
Syriopoulou14 Greece Children ≤11 years of age with I
Abate15 Mendoza, Argentina Children 0–180 months of age w
CV7=7-valent pneumococcal conjugate vaccine; SP= Streptococcus pneumoniae; AOM=aional Journal of Infectious Diseases 14S (2010) e3–e10
PCV7 to PCV13: rationale for expanded-valency vaccines
Despite the widespread use of the 7-valent pneumococcal con-
jugate vaccine (PCV7) and its direct and indirect beneﬁcial impact
on the burden of pneumococcal disease worldwide, disease caused
bynonvaccine serotypes and suboptimal vaccine coverage, particu-
larly in developing nations, has somewhatmitigated the beneﬁts of
the vaccine. A recent study1 on theburdenof pneumococcal disease
among children <5 years of age indicates that, in 2000, an estimated
14.5 million episodes of serious pneumococcal disease occurred
in children 1–59 months of age. Of the estimated 155.8 million
new cases of clinical pneumonia that occur each year, the majority
(151.8 million) occur in developing countries.2 Developing coun-
tries, particularly those in sub-Saharan Africa and South-East Asia,
bear a disproportionate childhood mortality burden of pneumo-
coccal disease.2,3 In 2004, there were more than 2 million deaths
due to pneumonia among children <5 years of age in developing
countries comparedwith about 1000 deaths in this patient popula-
tion in industrialized countries, making the total number of deaths
due to pneumonia among children <5 years about 2000-fold higher
in developing countries than in industrialized countries.3
While childhood pneumococcal vaccination is nearly universal
in Europe and the United States, vaccination coverage is much
less widespread in the developing world owing to a lack of health
care resources. One of the key factors in reducing the burden
of pneumococcal disease worldwide is to improve vaccination
coverage. In a transmission-dynamic model designed to assess the
direct and indirect effects of PCV7 at various levels of vaccination
coverage, Snedecor et al.4 found that the modeled yearly incidence
of invasive pneumococcal disease (IPD; cases per 100,000 popu-
lation) in children <2 years of age, children 2–4 years of age, and
adults ≥65 years of age would decrease dramatically up to 10 years
after vaccine introduction with increasing vaccination coverage.
In an assessment of the correlation between vaccination coverage
and child hospitalization rates due to IPD in 1 state in Venezuela,5
the incidence of IPD (pneumonia, meningitis, and sepsis) in infants
and children was directly proportional to the increase in vaccine
coverage.
Another key factor in reducing the burden of pneumococ-
cal disease is to expand coverage to include all or most of the
serotypes that cause pneumococcal disease. In most countries
that have implemented PCV7 vaccination, disease caused by
vaccine serotypes has decreased. However, nonvaccine serotypes
have emerged as major causes of pneumococcal disease in the
post-PCV7 era (Table 1),6–15 underscoring the need for expanded
Trends in Nonvaccine Serotypes
14 years of age Increase in 1, 19A, 7F; decrease in 6A
ositive culture
id
Increase in 1, 19A
ldren 6–24 Increase in nonvaccine serotypes from 26.5% to 59.4%;
increase in 19A; prevalence of 6A: stable
bacterial Most prevalent: 7F, 15B/C, 19A
h Most prevalent: 1, 5
l isolates Increase in 19F
mas,
2008)
Decrease in 1, 5
D Most prevalent: 19A, 1, 19F, 7F
PD or AOM Most prevalent in IPD: 7F, 9A, 3; most prevalent in AOM:
19A, 19F, 6A
ith IPD Most prevalent in children <2 years of age: 14, 5; most
prevalent in children <5 years of age: 1
cute otitis media; IPD= invasive pneumococcal disease.
